Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3-pyrrolidinylmethyl)piperazine) is an E3 ligase ligand-linker conjugate targeting cereblon (CRBN). This compound enables the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating selective protein degradation. It is valuable for research in targeted protein modulation and the exploration of E3 ligase interactions in cellular pathways. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-Pip-3-hydroxypropanoic acid is an E3 ligase ligand-linker conjugate designed to engage the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking target proteins to the ubiquitin-proteasome system. Its application in targeted protein degradation research makes it a valuable tool for studying protein regulation and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-C-COOH is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and a versatile linker. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), which facilitate targeted protein degradation. Its utility in chemical biology enables research applications in therapeutic development and the study of protein function and regulation. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 131 is designed as an E3 ligase ligand linked to a chemical moiety, serving as a crucial intermediate in the synthesis of the PROTAC molecule CPD-10. This conjugate facilitates targeted protein degradation by promoting the ubiquitination of specific substrates through E3 ligase recruitment. Its application in research includes the development of PROTACs for investigating protein function and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-(1-(3R-pyrrolidinylmethyl)piperazine)-Boc is an E3 ligase ligand-linker conjugate designed for the targeted protein degradation approach. This compound incorporates a CRBN-based ligand that facilitates the recruitment of E3 ligases for the selective ubiquitination of target proteins. It is primarily utilized in the synthesis of PROTACs, aiding researchers in the development of novel therapeutics that induce targeted degradation of disease-related proteins. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-6-F-5-azetidine-COOH is an E3 ligase ligand-linker conjugate designed for use in PROTAC (PROteolysis TArgeting Chimeras) synthesis. This compound features a CRBN-based ligand that facilitates specific protein degradation through the recruitment of E3 ligases. Its application is crucial for advancing research in targeted protein removal and therapeutic development within the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-C-COOH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN) ligand and linker moiety. This compound serves as a critical tool for the synthesis of PROTACs (Proteolysis Targeting Chimeras), which are designed for targeted protein degradation. Its versatility makes it valuable in studies focused on protein regulation and therapeutic intervention in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-azetidine is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand. This compound plays a pivotal role in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the targeted degradation of specific proteins. Its structure enables efficient binding to E3 ligases, making it a valuable tool for research in protein degradation strategies and therapeutic development. -
E3 Ubiquitin Ligase Ligands and Linkers for PROTACs
6-Aminocaproic acid-(S,R,S)-AHPC-Me is a ligand and linker designed for E3 ubiquitin ligase in proteolysis-targeting chimeras (PROTACs). This compound plays a critical role in the development of targeted protein degradation approaches, making it valuable in tumor research and related applications. Its utilization in synthesizing PVD-06 highlights its importance in advancing therapeutic strategies against cancer. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C6-COOH is an E3 ligase ligand-linker conjugate featuring a VHL ligand and a linker derived from (S,R,S)-AHPC. This compound facilitates the synthesis of PROTAC molecules, enabling targeted protein degradation. The unique structure promotes selective ubiquitination and subsequent proteasomal degradation of target proteins, providing valuable tools for research in protein regulation and disease model studies. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-Linker Conjugate 113 is an advanced tool designed for targeted protein degradation via the ubiquitin-proteasome system. This conjugate facilitates the recruitment of E3 ligases to specific substrates, thus promoting ubiquitination and subsequent degradation of target proteins. Its utility spans a range of applications, including drug discovery, cellular biology, and understanding protein turnover mechanisms in various disease states. -
Linker-E3 Ligase Ligand Conjugate
Pomalidomide 5-piperidylamine is a linker-E3 ligase ligand conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC PARP1 degrader-2, which selectively promotes the degradation of PARP1 protein. Its utility in research enables the study of targeted degradation pathways and the role of PARP1 in various cellular processes. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-COOH is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN)-based ligand, designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted protein degradation by harnessing the ubiquitin-proteasome system, thus providing a powerful tool for studies in protein regulation and degradation. Its applications extend to drug discovery and the development of novel therapeutic strategies, particularly in oncology and targeted therapy research. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-PEG3-C3 is an E3 ligase ligand-linker conjugate designed to facilitate the targeted degradation of proteins via the PROTAC (Proteolysis Targeting Chimeras) technology. This compound incorporates a VHL ligand and a PEG-based linker derived from (S,R,S)-AHPC, providing enhanced solubility and stability. Its applications include the development of novel therapeutic strategies for diseases associated with protein dysregulation. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-piperidine is an E3 ligase ligand-linker conjugate specifically designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound features a CRBN-based ligand that facilitates targeted protein degradation through the recruitment of the cereblon E3 ligase. Its unique structure enables efficient conjugation, making it a valuable tool for advancing research in targeted protein degradation and therapeutic discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidine-NH-Me is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of PROTACs (proteolysis-targeting chimeras). This compound features a CRBN-based ligand that engages with E3 ubiquitin ligases, enabling the targeted degradation of specific proteins within cellular systems. Its applications in chemical biology and therapeutic development include the study of protein regulation and the discovery of new drug candidates. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 122 is a specialized reagent designed for the synthesis of PROTAC degraders, specifically NR-11c. It combines an E3 ligase ligand with a linker, facilitating targeted protein degradation through the ubiquitin-proteasome system. This compound is essential for studies focused on E3 ligase-mediated degradation pathways and therapeutic applications in targeted cancer therapies. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-1-(piperidin-4-ylmethyl)piperidine is an E3 ligase ligand-linker conjugate designed for use in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features a CRBN-based ligand, facilitating the selective recruitment of target proteins for ubiquitination and subsequent degradation. It is a valuable tool for researchers studying targeted protein degradation and its therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand PG-piperidine-C2-OH is a conjugate designed for E3 ligase targeting, featuring a CRBN-based ligand linked to a piperidine moiety. This versatile linker compound serves as a crucial component in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the targeted degradation of proteins. Its application in chemical biology research enables the precise modulation of protein levels, contributing to studies in cancer therapeutics and other disease areas. -
E3 Ligase Ligand-Linker Conjugate
3-(2,6-Difluoro-4-(4-(2-hydroxyethyl)piperidin-1-yl)phenyl)piperidine-2,6-dione functions as an E3 ligase ligand-linker conjugate with a CRBN-based ligand. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), serving as a valuable tool in targeted protein degradation studies. It can be utilized in research applications involving modulation of cellular pathways and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG2-OMs is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the recruitment of the cereblon (CRBN) E3 ligase. This compound effectively enhances the efficacy of proteolysis-targeting chimeras (PROTACs), specifically enabling the degradation of epidermal growth factor receptor (EGFR) in research applications. Its versatile functionality makes it a valuable tool in studies focused on protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-azetidine is a conjugate that targets the E3 ligase cereblon (CRBN) through its ligand-linker composition. This reagent is essential for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating targeted protein degradation research. Its application supports studies in protein regulation and therapeutic development in various disease contexts, including cancer and neurodegenerative disorders. -
E3 Ligase Ligand-Linker Conjugate
KRAS G12C degrader-2 is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a functional linker. This compound facilitates the development of PROTAC (proteolysis-targeting chimeras), enabling targeted degradation of KRAS G12C-mutant proteins. It is a valuable tool for researchers investigating the therapeutic potential of targeted protein degradation in cancer treatment. -
E3 Ligase Ligand-Linker Conjugates
(3S)Lenalidomide-piperazine-C-piperidine acts as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound facilitates the design and synthesis of PROTACs, specifically enabling the development of PROTAC ER Degrader-11. Its application in targeted protein degradation research makes it a valuable tool for studying ubiquitin-mediated cellular processes. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-6-F-5-piperazine benzenesulfonate is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a linker structure. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), which facilitate targeted protein degradation. It serves as a valuable tool in drug discovery and development by enabling the selective modulation of protein levels within cellular systems. -
Crosslinker-E3 Ligase Ligand Conjugate
Pomalidomid-C6-PEG3-butyl-N3 is a crosslinker-E3 ligase ligand conjugate designed for click chemistry applications. This reagent features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and ring strain-promoted alkyne-azide cycloaddition (SPAAC) reactions. Pomalidomid-C6-PEG3-butyl-N3 serves as an essential building block for the development of proteolysis-targeting chimeras (PROTACs) and targeted protein degraders, facilitating advancements in targeted protein degradation research. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-C-piperazine is an E3 ligase ligand-linker conjugate designed for the targeted degradation of specific proteins. The compound features a cereblon (CRBN)-based ligand, enabling the synthesis of PROTAC (Proteolysis Targeting Chimera) molecules. This reagent is valuable for research applications involving protein modulation and the study of protein homeostasis pathways. It may facilitate the development of targeted therapies in various disease models, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-propargyl-NHCH3 is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a propargyl linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs) by promoting targeted protein degradation. Its applications include advancing research on protein regulation and therapeutic development in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-S-COOH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand and a linker moiety. This compound facilitates the synthesis of Proteolysis Targeting Chimeras (PROTACs), which are innovative tools for targeted protein degradation. Its applications include fundamental research in cellular signaling pathways, drug development, and therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
(R,S,S)-VH032-PEG5-N3 is an E3 ligase ligand-linker conjugate that combines a VHL ligand, derived from VH032, with a five-unit PEG linker. This compound serves as a versatile click chemistry reagent featuring an azide group, which facilitates copper-catalyzed azido-alkyne cycloaddition (CuAAc) when interacting with alkyne-containing molecules. Additionally, it is capable of undergoing strain-promoted azide-alkyne cycloaddition (SPAAC) with compounds containing DBCO or BCN groups, making it valuable for targeted protein degradation studies and related applications in chemical biology. -
E3 Ligase Ligand-Linker Conjugate
2-(2,6-Dioxopiperidin-3-yl)phthalimidine-Piperazine-piperidine is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the ubiquitin-proteasome pathway. This compound contains a CRBN-based ligand and a versatile linker, enabling the synthesis of PROTAC (Proteolysis Targeting Chimeras). Its utility in research applications includes investigating the modulation of specific protein levels and the development of novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 221 is designed to selectively engage E3 ligases through a CRBN-based ligand and a linker component. This conjugate facilitates the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation for various therapeutic applications. It serves as a valuable tool in chemical research focused on modulating protein levels within biological systems. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-C-piperazine trihydrochloride is an E3 ligase ligand-linker conjugate that utilizes a cereblon (CRBN) ligand, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs). This compound serves as a valuable tool in chemical biology for the targeted degradation of proteins, enabling researchers to investigate cellular functions and therapeutic interventions in various diseases. Its strategic design enhances the specificity and efficacy of protein degradation applications in research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-o-PEG2-acid is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation via PROTAC technology. This compound incorporates a thalidomide-derived cereblon ligand, facilitating the ubiquitination and subsequent proteasomal degradation of target proteins. It is valuable in research applications aimed at understanding protein regulation and exploring therapeutic strategies for various diseases. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-CO is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This reagent is designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs), aiding in targeted protein degradation studies. Its specific interactions facilitate the investigation of E3 ligase-mediated pathways, making it valuable for research applications in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG5-tosyl is an E3 ligase ligand-linker conjugate that utilizes a Thalidomide-derived cereblon ligand in combination with a 4-unit polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC technology, facilitating the recruitment of E3 ligases to target proteins for ubiquitination and subsequent degradation. Thalidomide-O-PEG5-tosyl demonstrates reactivity with nucleophiles, including amine and hydroxy-containing molecules, making it a valuable tool for researchers studying targeted protein degradation and related pathways. -
E3 Ligase Ligand-Linker Conjugate
Dimethyl 3-hydroxyphthalate-amido-C4-N3 is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound serves as a crucial component in the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation. It facilitates the recruitment of E3 ligases, which are essential for the ubiquitination process, making it valuable for research in targeted therapy and protein regulation studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-3,8-diazabicyclo[3.2.1]octane-Boc is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a linker structure, facilitating the synthesis of PROTACs. This compound is instrumental in targeted protein degradation research, enabling precise modulation of protein levels within cells. Its unique design allows for effective recruitment of E3 ligases in various biological systems, making it a valuable tool for exploring protein homeostasis and therapeutic applications in diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C6-Br is an E3 ligase ligand-linker conjugate that utilizes a thalidomide-derived CRBN ligand, designed for applications in PROTAC technology. This compound is intended for the selective degradation of target proteins by facilitating the formation of protein degrader molecules, such as PROTAC EZH2 Degrader-12. Its unique structure allows for the targeted modulation of protein levels, making it a valuable tool for research into targeted protein degradation and related therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-cyclohexane-C-COOH is a conjugate that serves as an E3 ligase ligand-linker. This compound features a cereblon (CRBN)-based ligand combined with a cyclohexane linker, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs). It is employed in research to explore targeted protein degradation mechanisms and to develop innovative therapeutic strategies against various diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C4-Br is an E3 ligase ligand-linker conjugate derived from thalidomide, specifically targeting the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the formation of PROTACs, enabling targeted protein degradation, with applications in cancer research and therapeutic development. Thalidomide-4-O-C4-Br can be utilized to generate conjugates such as PROTAC EZH2 Degrader-10, which are designed to selectively degrade specific proteins of interest in a cellular context. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperazine-C-azetidine TFA is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand integrated with a linker moiety. This compound is designed for the synthesis of PROteolysis TArgeting Chimeras (PROTACs), facilitating targeted protein degradation pathways. Its application in research primarily includes the exploration of E3 ligase-mediated ubiquitination processes and the development of targeted therapies in drug discovery. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-N3 is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and an optimized linker moiety. This compound is designed to facilitate the synthesis of proteolysis-targeting chimeras (PROTACs), enabling selective degradation of target proteins. Its versatile applications in chemical biology and targeted protein modulation make it a valuable tool for research in drug discovery and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand 63-N-CH2-Ph-O-CH3 is an E3 ligase ligand-linker conjugate that incorporates a CRBN-based ligand and a flexible linker. This compound is designed for the synthesis of PROTACs (proteolysis-targeting chimeras), facilitating targeted protein degradation. Its unique structure supports the recruitment of E3 ligases to target proteins, enabling efficient modulation of protein levels in various research applications, including cancer therapy and cellular signaling studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-piperazine TFA is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs. This compound features a cereblon (CRBN)-based ligand, enabling targeted ubiquitination and proteasomal degradation of specific proteins. Its unique structure facilitates the development of bifunctional constructs for targeted protein modulation in therapeutic research applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-O-piperidin is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and a linker region. This compound is designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling selective degradation of target proteins via the ubiquitin-proteasome system. Its application in chemical biology facilitates targeted protein modulation and offers insights into protein function and disease mechanisms. -
Antiproliferative
Pomalidomide-C2-amide-C5-azide is an E3 ligase linker conjugate that targets selected proteins for ubiquitination and degradation via the PROTAC (proteolysis-targeting chimera) approach. This compound demonstrates notable antiproliferative activity and can be utilized in research applications focused on CDK9 modulation. Its design allows for the synthesis of potent PROTAC molecules, advancing studies in targeted protein degradation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S)-Deoxy-thalidomide-Pip-3-hydroxypropanoic acid hydrochloride is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN) for targeted protein degradation. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), making it a valuable tool for exploring targeted therapies in cancer and other diseases. Its unique structure enhances the selective degradation of specific proteins, aiding in the study of protein dynamics and function within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-Pip-CO-piperazine hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a cereblon (CRBN)-based ligand and a piperazine linker, facilitating the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a valuable tool for researchers investigating innovative therapeutic strategies through modulation of protein levels via the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperazine hydrochloride is an E3 ligase ligand-linker conjugate targeting cereblon (CRBN). This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling the selective degradation of target proteins. Its utility in drug development and research highlights its potential for modulating protein levels in various cellular contexts.
